Current use of combined hormonal contraception is associated with glucose metabolism disorders in perimenopausal women. Issue 6 (December 2020)

• Record Type: Journal Article
• Authors: Mosorin, Maria-Elina; Haverinen, Annina; Ollila, Meri-Maija; Nordström, Tanja; Jokelainen, Jari; Keinänen-Kiukaanniemi, Sirkka; Puukka, Katri; Ruokonen, Aimo; Auvinen, Juha; Piltonen, Terhi; Morin-Papunen, Laure; Tapanainen, Juha S
• Is Part Of: European journal of endocrinology. Volume 183:Issue 6(2020)
• Page Start: 619
• Page End: 626
• Publication Date: 2020-12
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EJE-20-0406
• Languages: English
• ISSNs: 0804-4643

Abstract

Abstract : Objective: The use of combined hormonal contraceptives (CHCs) worsens glucose tolerance, but the risk for glucose metabolism disorders remains controversial. Design: The study is a prospective longitudinal population-based cohort study. Methods: The study was based on a cohort population that comprised 1879 women born in 1966. At age 46, the women answered a questionnaire on contraceptive use and underwent an oral glucose tolerance test. Glucose metabolism indices were evaluated in current CHC ( n = 153), progestin-only contraceptive (POC, n = 842), and non-hormonal contraceptive users ( n = 884). Results: In the entire study population, current CHC use was significantly associated with prediabetes (OR: 2.0, 95% CI: 1.3–3.2) and type 2 diabetes (OR: 3.3, 95% CI: 1.1–9.7) compared to non-hormonal contraceptive use. After 5 years of use, the prediabetes risk increased 2.2-fold (95% CI: 1.3–3.7) and type 2 diabetes risk increased 4.5-fold (95% CI: 1.5–13.5). Compared with the current POC use, current CHC use was significantly associated with prediabetes (OR: 1.9, 95% CI: 1.2–3.0). Current POC use was not associated with any glucose metabolism disorders. The results prevailed after adjusting for BMI and socioeconomic status. Conclusions: CHC use in perimenopausal women was associated with a significantly increased risk of glucose metabolism disorders. This association should be considered in women with increased metabolic risk.